Thelansis

Lantern Pharma Inc., an AI company pioneering cancer therapies, announces that the FDA has granted Fast Track Designation for its investigational drug, LP-184, to treat Glioblastoma. Currently in a Phase 1A clinical trial, LP-184 is being evaluated for safety and tolerability in various solid tumors, including GBM. Optimized through Lantern’s AI platform, RADR®, the drug aims to target mechanisms to combat challenging cancers. RADR® integrates over 100 billion data points, fueling Lantern’s drug portfolio and collaborations. Publish Date: 15-10-2024   Source: Lantern Pharma Inc. Glioblastoma (GBM) is the most aggressive among the diffuse gliomas originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumors, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, ...

  Glioblastoma (GBM) is the most aggressive among the diffuse gliomas originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumors, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, except in cases where it emerges following therapeutic brain irradiation for other conditions. The genetic anomalies identified, such as EGFR gene amplification (7p12), TP53 gene mutations (17p13.1), and chromosome 10 loss, vary depending on the tumor's nature: primary glioblastoma (de novo) or secondary glioblastoma (arising from a benign astrocytic tumor). Glioblastomas can develop at any age. They are most commonly observed in patients between 45 and 70, making up 70% of cases in this age group. Typically, these tumors are situated in the brain hemispheres but can occur throughout ...

  Glioblastoma (GBM) is the most aggressive diffuse glioma of the astrocytic lineage. It is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM treatment is complex, initially consisting of maximally safe surgical resection followed by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy. Glioblastoma has an incidence of 2 to 3.4 per 1,00,000 population in the US and Europe. Thelansis’s “Glioblastoma (GBM) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glioblastoma (GBM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Gli...

Glioblastoma (GBM) is the most aggressive diffuse glioma of astrocytic lineage and is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM treatment is complex, initially consisting of maximally safe surgical resection followed by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy.  GBM comprised of primary and secondary types, constituting distinct disease entities which evolve through different genetic pathways, affect patients at different ages, and likely differ in prognosis and response to therapy.  Primary de novo GBM accounts for more than 80% of GBM (6), occurs in older patients (mean age = 64 years), and typically shows epidermal growth factor receptor (EGFR) over expression, PTN (MMC I) mutation, CDKN2A (p16) deletion, and less frequently MDM2 amplification.    Epidemiology- Glioblastoma has an incidence of 2 to 3.4 per 100,000 population in US and Europe.   The competiti...